nusinersen

all catalysts(0)

nothing on the calendar yet

News(7)

• Boehringer, Envisagenics sign $1B multi-target oncology collaboration
  Boehringer Ingelheim and AI drug discovery company Envisagenics have agreed to a potential $1 billion multi-year pact that will task Boehringer with validating tumor-specific targets.
  fiercebiotech · 12d ago
• Scholar Rock secures first FDA approval for muscle-targeting rare disease drug
  Scholar Rock’s spinal muscular atrophy drug, now to be called Isembyld, was originally rejected in September 2025, when the FDA cited compliance problems at a third-party manufacturer.
  biospace · 19d ago
• Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipeline
  After Jenny Pearson’s daughter Elise first had a seizure at 16 months old, an MRI came back clean—her brain “looked beautiful,” Pearson recalled to Fierce. But a follow-up scan a year later, just d…
  fiercebiotech · 29d ago
• FDA approves Ionis’ antisense drug as first targeted therapy for Alexander disease
  Zanvastro, an antisense oligonucleotide therapy, represents the first independent neurology launch for Ionis Pharmaceuticals, which intends to leverage the foothold for more approvals in rare neuro…
  biospace · 1mo ago
• Biogen’s targeted ALS treatment is reversing decline in some patients. Can more be helped?
  Three years after Qalsody was approved by the FDA as the first drug to target a genetic cause of ALS, some patients are reporting not only disease stabilization but also improvement of symptoms.
  biospace · 1mo ago
• Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push
  Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.
  biopharma_dive · 2mo ago
• ‘We have what we need to grow:’ Biogen CEO happy to ease off the M&A for a while
  Biogen's business development team may have been busy in recent years, but CEO Christopher Viehbacher is easing off the acquisitions for a while.
  fiercebiotech · 2mo ago